Last reviewed · How we verify
Havrix 720 Junior
Havrix 720 Junior is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.
Havrix 720 Junior is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. Used for Prevention of hepatitis A infection in children aged 1-18 years.
At a glance
| Generic name | Havrix 720 Junior |
|---|---|
| Sponsor | Chiang Mai University |
| Drug class | Inactivated viral vaccine |
| Target | Hepatitis A virus surface antigen |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) hepatitis A virus antigen that triggers both humoral and cellular immune responses. This leads to the production of protective antibodies (anti-HAV IgG) and memory B cells, conferring long-term immunity against hepatitis A infection. The 720 junior formulation contains a lower antigen dose (360 ELISA units per 0.5 mL dose) designed for pediatric use.
Approved indications
- Prevention of hepatitis A infection in children aged 1-18 years
Common side effects
- Injection site soreness or erythema
- Fever
- Headache
- Fatigue
Key clinical trials
- Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents (PHASE3)
- To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (PHASE3)
- To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs (PHASE3)
- Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Havrix 720 Junior CI brief — competitive landscape report
- Havrix 720 Junior updates RSS · CI watch RSS
- Chiang Mai University portfolio CI